Tetradecylthioacetic Acid for Health & Longevity

Evidence Review created on 08/01/2026 using AI4L / Opus 4.8

Also known as: TTA, Tetradecyl Thioacetic Acid, 2-(Tetradecylthio)acetic Acid, 1-(Carboxymethylthio)tetradecane

Motivation

Tetradecylthioacetic acid (TTA) is a laboratory-made fatty acid built to behave differently from the fats we eat. It has a sulfur atom placed where the body would normally begin to burn the fat for fuel, so the molecule cannot be used up for energy. Instead, it lingers inside cells and acts like a signal, switching on the genes that tell the body to burn its own stored fat and to calm inflammation. Because of this, researchers have studied it mainly as a way to lower blood fats and improve how the body handles fat and sugar.

The compound was created by Norwegian researchers in the 1980s and 1990s and moved into a handful of small human studies in people with diabetes, a skin condition called psoriasis, and viral infection. It has never become an approved medicine and today circulates mostly as a niche, unregulated powder, which makes separating genuine promise from hype important for anyone considering it.

This review examines what is actually known about tetradecylthioacetic acid: how it works, the benefits and risks suggested by animal and early human research, and the large gaps that remain before its role in long-term health can be judged.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Tetradecylthioacetic acid

The Grokipedia entry gives a broad, referenced overview of the compound’s chemistry, its action on fat-sensing cell receptors, and its preclinical and early clinical research. It is a useful lay-accessible starting point that consolidates scattered findings.

Examine

Tetradecyl Thioacetic Acid

Examine’s page summarizes the compound as a fat-burning cell-receptor activator studied mainly for fat loss and blood-fat lowering, and it flags the near-total absence of human outcome data. It is a balanced, independent reference on what the evidence does and does not support.

ConsumerLab

No ConsumerLab article on tetradecylthioacetic acid exists. ConsumerLab tests widely sold consumer supplements, and this compound is a niche, largely unregulated research chemical that falls outside its testing scope.

Systematic Reviews

No systematic reviews or meta-analyses for Tetradecylthioacetic Acid were found on PubMed as of August 1, 2026.

Mechanism of Action

Tetradecylthioacetic acid is a synthetic “3-thia fatty acid” — a 16-carbon fatty acid in which a sulfur atom replaces a carbon at the third position from the acid end. That single swap has an outsized effect: normal fatty acids are dismantled for energy by a process called beta-oxidation (the stepwise mitochondrial “burning” of fat), but the sulfur atom blocks this process at its starting point, so TTA itself is essentially non-burnable. Rather than being consumed, it accumulates in cells and behaves as a long-lived regulatory signal.

Its primary action is as a pan-agonist of the peroxisome proliferator-activated receptors (PPARs, a family of nuclear receptors that switch on genes governing fat transport, fat burning, and inflammation). TTA activates all three subtypes, in the order PPAR-α > PPAR-δ > PPAR-γ, with roughly micromolar potency at PPAR-α. Through PPAR-α and PPAR-δ it upregulates the machinery for taking up and oxidizing fatty acids, expands the number and activity of mitochondria (the cell’s fat-burning compartments), and increases hepatic fat burning and ketone production. The proposed net effect — sometimes called the “hepatic fatty acid drainage” hypothesis — is that the liver is driven to pull fatty acids out of the blood and other tissues and burn them, lowering circulating fats and reducing fat storage.

TTA has two further, partly independent actions. As a sulfur-containing molecule it has direct antioxidant activity, scavenging free radicals and inhibiting the oxidation of LDL (“bad” cholesterol-carrying particles). It also dampens inflammation, lowering signaling molecules such as tumor necrosis factor-alpha (TNF-α, a master pro-inflammatory messenger).

Where mechanistic explanations compete: some anti-inflammatory and anti-proliferative effects of TTA persist in cells and animals lacking PPAR-α, indicating both PPAR-dependent and PPAR-independent pathways are at work. Proponents emphasize the receptor-driven metabolic reprogramming; a competing view holds that a substantial share of TTA’s antioxidant and anti-inflammatory benefit comes from its direct chemistry and its incorporation into cell membranes, independent of gene activation. Both mechanisms are supported by experimental data and are best regarded as complementary.

Key pharmacological properties (from the phase-1 human study and animal work):

Selectivity: Pan-PPAR agonist (PPAR-α > PPAR-δ > PPAR-γ); not receptor-selective.
Half-life: After oral dosing, a lag of about 1.5 hours precedes rapid absorption, with peak blood levels at roughly 2.5–4.5 hours and a slower elimination phase; a precise elimination half-life in humans has not been firmly established, and the compound is expected to persist far longer inside tissues because it cannot be burned.
Tissue distribution: Taken up broadly and incorporated into cellular phospholipids and complex lipids, with accumulation in liver, heart, and adipose tissue in animals.
Metabolism: Not degraded by beta-oxidation. It undergoes limited alpha-oxidation, Δ9-desaturation (producing a measurable desaturated metabolite, TTA:1n-8), and oxidation of its sulfur atom to sulfoxide and sulfone forms. It is not a well-characterized substrate of the major cytochrome P450 (CYP, the liver’s main drug-metabolizing enzyme system) pathways.

Historical Context & Evolution

Tetradecylthioacetic acid originated as a research tool. In the 1980s and 1990s, Rolf K. Berge and colleagues at the University of Bergen in Norway synthesized a series of sulfur-substituted fatty acids to probe how the liver regulates fat burning. TTA — structurally a modified relative of the natural fatty acid myristic acid — stood out because it robustly stimulated fatty acid oxidation while being non-burnable itself, making it ideal for studying fat metabolism.

Its original intended use, therefore, was mechanistic investigation rather than treatment. Interest shifted toward health optimization when animal studies showed that TTA lowered blood triglycerides and cholesterol, prevented diet-induced obesity and insulin resistance, and reduced markers of inflammation and oxidative stress. These findings positioned it as a candidate hypolipidemic and anti-inflammatory agent, and a Norwegian company (Thia Medica AS) advanced it into first-in-human safety testing and small exploratory efficacy trials in the 2000s.

The actual findings of this era were mixed but coherent: a phase-1 study established tolerability; small trials in type 2 diabetes, HIV-related high blood fats, and psoriasis showed consistent lipid lowering and reduced inflammatory markers, but no dramatic metabolic transformation and no glucose-lowering. Development then stalled — not because the compound was disproven, but because the effects, while real, were modest, funding was limited, and the field’s attention moved to other PPAR agonists. The evidence base has not been formally overturned; it simply remains thin. What changed over time was enthusiasm, not the underlying data, and the compound’s standing is best described as promising-but-unproven rather than either validated or discredited.

Expected Benefits

The benefits below are drawn from animal models, human cell studies, and four small human trials. No large or long-term human outcome trials exist, so even the best-supported benefits rest on modest evidence. Benefits are framed for a proactive, risk-aware adult considering the compound for metabolic and longevity purposes.

Medium 🟩 🟩

Improvement of Blood Lipid Profile

TTA’s most reproducible effect in humans is lowering of blood fats. In men with type 2 diabetes taking 1 gram daily for 28 days, LDL (“bad”) cholesterol fell and the LDL-to-HDL ratio improved, with a rise in the protective apolipoproteins that make up HDL (“good” cholesterol) particles. Similar reductions in total cholesterol, LDL, and triglycerides (the main storage fat in blood) appeared in a placebo-controlled psoriasis trial and a pilot in people with treatment-related high blood fats. The proposed mechanism is receptor-driven redistribution and increased burning of circulating fats. The main limitations are very small samples, short duration, and mostly male participants.

Magnitude: LDL cholesterol fell roughly 10–12% (about 4.2 to 3.7 mmol/L) over 28 days in type 2 diabetes, with the LDL/HDL ratio down about 8% (4.00 to 3.66).

Low 🟩

Reduction of Inflammatory Markers

Across the human pilot studies, TTA lowered circulating markers of inflammation alongside its lipid effects. In people with HIV-related high blood fats it reduced tumor necrosis factor-alpha (TNF-α), and in psoriasis it reduced TNF-α, interleukin-8 (IL-8, a signal that recruits inflammatory cells), and vascular cell adhesion molecule-1 (VCAM-1, a marker of activated, “sticky” blood-vessel lining). The proposed mechanism combines PPAR-driven gene changes with direct, receptor-independent anti-inflammatory chemistry. Evidence is limited to small, short trials in specific patient groups, so relevance to healthy adults is uncertain.

Magnitude: Statistically significant reductions in TNF-α, IL-8, and VCAM-1 over 28 days; exact effect sizes were not reported in the trials.

Increased Fatty Acid Oxidation and Mitochondrial Activity

TTA increases the body’s capacity to burn fat. In human muscle and liver cells it raised fatty acid oxidation, and in animals it multiplied mitochondria and increased hepatic fat burning and ketone production. For a longevity-oriented reader, greater fat-oxidizing capacity and mitochondrial density are plausibly favorable metabolic traits. The evidence is strong mechanistically and in cell and animal systems but has not been translated into demonstrated clinical outcomes in humans, and in the diabetes trial fat-burning gains did not improve blood sugar control.

Magnitude: Not quantified in available studies.

Speculative 🟨

Protection Against Fat Gain and Insulin Resistance

In rodents, TTA prevented high-fat-diet-induced weight gain and insulin resistance and reduced fat-tissue mass, an effect attributed to draining and burning excess fat via PPAR-α. This is one of the most striking preclinical findings, but it has not reproduced as a metabolic or weight benefit in the small human trials, where body weight and glucose handling were largely unchanged. The basis is therefore animal and mechanistic only.

Cardiovascular and Anti-Atherosclerotic Protection

TTA reduced arterial narrowing after injury in rabbits, limited plaque development in atherosclerosis-prone mice beyond its cholesterol-lowering effect, and improved heart function in animal models of heart failure. Combined with its antioxidant and LDL-oxidation-blocking activity, this suggests possible cardiovascular benefit. No human cardiovascular outcome data exist, so this remains a mechanistic and animal-based hypothesis.

Antioxidant Protection

As a sulfur-containing molecule, TTA directly scavenges free radicals, interacts with the superoxide radical, and inhibits the oxidation of LDL particles and DNA damage markers in laboratory and animal systems. Whether this translates into meaningful antioxidant protection at achievable human doses is untested; the basis is in-vitro and animal evidence only.

Benefit-Modifying Factors

Genetic variation in fat-sensing receptors: Because TTA works largely through PPAR-α and PPAR-δ, common variants in the genes encoding these receptors and their partner PPARGC1A (which builds mitochondria) could plausibly amplify or blunt responses. This has not been directly studied for TTA, so it remains an inference from the mechanism.
Baseline blood-fat levels: The lipid-lowering signal was clearest in people who started with elevated or disturbed blood fats (diabetes, HIV-related high blood fats, psoriasis). Individuals with already-optimal lipids may see little change, as is typical for fat-lowering agents.
Sex-based differences: The human efficacy studies enrolled predominantly or exclusively men. Whether women respond similarly is unknown, and animal data suggest sex hormones can influence PPAR-driven fat metabolism, so female responses cannot be assumed equivalent.
Pre-existing metabolic and inflammatory conditions: Benefits were observed specifically in people with underlying dyslipidemia or chronic inflammation. Those with active inflammatory or metabolic disease may have more to gain than metabolically healthy individuals.
Age: No age-stratified human data exist. Older adults, who tend to have declining mitochondrial function and higher baseline lipids, are a plausible group for larger effects, but also carry more competing conditions and medications; this is untested for TTA.

Potential Risks & Side Effects

TTA has a limited human safety record — a phase-1 study and three short trials, together involving roughly 50 people, with generally good tolerability. Consequently, most serious risks are theoretical, extrapolated from its drug class (fatty-acid PPAR-α agonists, which behave much like the fibrate cholesterol drugs) and from animal studies. Risks are framed for a self-directed adult who may source and use the compound outside medical supervision.

Low 🟥

Mild Gastrointestinal and General Adverse Events

In the phase-1 study of healthy men dosed up to 1 gram daily for a week, only a few adverse events of mild severity were reported, with no clinically significant changes in blood counts or blood chemistry. This is the most directly observed risk category. The main caveat is that exposures were short and samples tiny, so uncommon or delayed effects would not have been detected.

Magnitude: Few, mild adverse events at doses up to 1 g/day over 7–28 days; no serious events reported.

Depletion of Beneficial Omega-3 Fatty Acids

By driving fat oxidation, TTA appears to consume polyunsaturated fats preferentially. In the type 2 diabetes trial, blood levels of the omega-3 fats docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) fell measurably. Because these omega-3s are themselves cardioprotective and anti-inflammatory, an unintended drop could partly offset TTA’s benefits, particularly with prolonged use. The mechanism is increased oxidation of long-chain polyunsaturated fats.

Magnitude: Roughly a 13% fall in DHA and 10% fall in EPA over 28 days at 1 g/day.

Speculative 🟨

Liver Enzyme Elevation and Hepatic Effects

As a potent PPAR-α agonist, TTA causes marked liver enlargement and peroxisome proliferation in rodents, and drugs in this class can raise liver enzymes in humans. Human trials to date showed no significant liver-chemistry changes, but they were short. The concern is mechanistic and class-based; longer or higher-dose human exposure could plausibly stress the liver, warranting monitoring.

Muscle Toxicity, Especially With Statins

Fibrate-class fat-lowering agents can cause muscle inflammation and, rarely, muscle breakdown, with the risk rising sharply when combined with statins. TTA shares the class mechanism, so a similar risk is plausible though never demonstrated for TTA specifically. The basis is class analogy and mechanism, not direct evidence.

Gallstones, Kidney Markers, and Homocysteine

Fibrate-class agents are associated with gallstone formation, small reversible rises in blood creatinine (a kidney marker), and increases in homocysteine (an amino acid linked to vascular risk). None of these have been reported for TTA, but they are recognized class effects that cannot be excluded on current data.

Rodent Liver Tumors (Species-Specific Concern)

Sustained PPAR-α activation causes liver tumors in rodents. This effect is now understood to be largely rodent-specific and driven by biology that operates differently in humans, so the human cancer relevance is thought to be low. It is noted for completeness because it shaped historical caution around this drug class; the basis is animal data whose human applicability is limited.

Risk-Modifying Factors

Genetic variation in metabolism and transport: Variants affecting how fatty-acid-based drugs are handled, or in the PPAR-α gene itself, could in principle influence both efficacy and susceptibility to class side effects such as muscle or liver stress. This is unstudied for TTA and inferred from its class.
Baseline liver and kidney biomarkers: Individuals starting with elevated liver enzymes or reduced kidney function are the group in which class-based hepatic and renal effects would most plausibly matter, making baseline values a key modifier of risk.
Sex-based differences: With human safety data drawn almost entirely from men, sex-based differences in adverse effects are unknown. Fibrate-class agents can affect the sexes somewhat differently, so caution is warranted in extrapolating the male safety record to women.
Pre-existing conditions: People with liver disease, gallbladder disease, significant kidney impairment, or muscle disorders are the populations in whom class-based risks would concentrate, and in whom the sparse TTA safety data provide the least reassurance.
Age: Older adults typically take more interacting medications (notably statins) and have reduced organ reserve, plausibly raising the consequence of any muscle, liver, or kidney effect. No age-specific TTA safety data exist.

Key Interactions & Contraindications

Because TTA has essentially no formal interaction studies, the interactions below are extrapolated from its class as a fatty-acid PPAR-α agonist that behaves like the fibrate cholesterol drugs.

Statins (atorvastatin, simvastatin, rosuvastatin): Additive risk of muscle inflammation and, rarely, muscle breakdown. Severity: caution to avoid in combination. Consequence: myopathy or rhabdomyolysis (severe muscle breakdown that can harm the kidneys). Mitigation: avoid routine combination; if co-used, monitor for muscle pain and check creatine kinase.
Other fibrates (fenofibrate, gemfibrozil): Overlapping mechanism; stacking offers little added benefit and compounds class risks. Severity: avoid. Consequence: heightened muscle, liver, and gallstone risk.
Warfarin and other blood thinners: Fibrate-class agents can potentiate warfarin, increasing bleeding risk. Severity: caution. Consequence: elevated INR (international normalized ratio, a measure of blood-clotting time) and bleeding. Mitigation: monitor INR closely and adjust dose if co-used.
Blood-sugar-lowering drugs (sulfonylureas such as glipizide; insulin): Class agents may enhance glucose lowering. Severity: monitor. Consequence: hypoglycemia. Mitigation: monitor blood glucose, particularly early in use.
Over-the-counter agents (NSAIDs, non-steroidal anti-inflammatory painkillers such as ibuprofen; niacin): High-dose niacin combined with fibrate-class agents raises muscle-toxicity risk; NSAIDs share renal-handling pathways that could matter in impaired kidneys. Severity: caution. Consequence: additive muscle or kidney stress.
Supplement interactions (additive lipid and inflammation effects): Omega-3 fish oil, red yeast rice (which contains a natural statin), berberine, and garlic all lower blood fats and could be additive with TTA. Omega-3 supplementation is also directionally sensible because TTA appears to deplete DHA and EPA. Severity: mostly additive/beneficial but monitor; red yeast rice adds statin-like muscle risk.
Other interventions: Combining TTA with other strong PPAR agonists (e.g., experimental pan-PPAR drugs) is untested and would compound class risks.
Populations who should avoid it: Pregnant or breastfeeding individuals (no reproductive safety data); people with active liver disease (e.g., Child-Pugh Class B or C), significant kidney impairment (e.g., eGFR, a measure of kidney filtration, <30 mL/min/1.73 m²), symptomatic gallbladder disease, or a history of statin- or fibrate-induced muscle injury; and anyone unable to arrange basic laboratory monitoring, given the unregulated supply.

Risk Mitigation Strategies

Low starting dose with gradual escalation: Because human data span only 200–1000 mg daily, beginning at the low end (e.g., 200 mg daily) and increasing over several weeks toward the studied 1000 mg limits exposure while tolerability is assessed, reducing the chance of unrecognized gastrointestinal, liver, or muscle effects.
Baseline and periodic liver and muscle monitoring: Checking liver enzymes (ALT and AST) and creatine kinase (CK, a muscle-damage marker) before starting and every 4–12 weeks addresses the class-based risks of liver enzyme elevation and muscle toxicity, allowing discontinuation before harm accumulates.
Avoid or carefully monitor statin co-use: Not combining TTA with statins — or, if unavoidable, watching for muscle pain and checking CK — directly targets the most consequential class interaction (myopathy and rhabdomyolysis).
Concurrent omega-3 intake: Taking supplemental EPA and DHA (e.g., 1–2 g/day fish oil) offsets the measured depletion of these beneficial omega-3 fats, mitigating a specific documented effect of TTA.
Kidney and gallbladder awareness: Confirming adequate kidney function (eGFR) at baseline and remaining alert to gallbladder symptoms addresses the class risks of rising creatinine and gallstone formation, prompting evaluation if symptoms arise.
Avoidance in higher-risk groups: Not using TTA during pregnancy or breastfeeding, or with significant liver, kidney, gallbladder, or muscle disease, prevents exposure in exactly the populations where the sparse safety data offer the least protection.

Therapeutic Protocol

There is no established, validated protocol for tetradecylthioacetic acid; the following reflects the doses and practices used by the researchers who studied it, chiefly the University of Bergen group and Thia Medica AS.

Standard studied dose: Human trials used 1000 mg (1 gram) of TTA taken orally once daily. The phase-1 study evaluated 200, 600, and 1000 mg daily; efficacy studies in diabetes, HIV-related high blood fats, and psoriasis used 1000 mg daily.
Competing approaches: No competing clinical protocols exist. The only meaningful alternative framing is TTA as a stand-alone agent versus TTA layered onto lifestyle change — the HIV pilot deliberately combined it with a cholesterol-lowering diet, and the diet-plus-compound approach is the more evidence-consistent one. Neither has been established as superior.
Originators: The dosing and clinical testing were developed by Rolf K. Berge and colleagues at the University of Bergen and commercialized by Thia Medica AS; there is no independent clinic or practitioner protocol.
Best time of day: Not systematically studied. As a fatty acid taken once daily, it is reasonably taken with a meal containing fat to aid absorption; trials used once-daily oral dosing without a specified time.
Half-life considerations: Oral absorption follows an initial lag of about 1.5 hours; blood levels peak at roughly 2.5–4.5 hours. Because the molecule cannot be burned and is incorporated into tissues, its biological persistence is expected to far exceed its blood residence, supporting once-daily dosing.
Single versus split dosing: All human studies used a single daily dose, and there is no evidence that splitting doses offers any advantage.
Genetic considerations: No pharmacogenetic guidance exists. Variants in PPAR-α/δ pathway genes could theoretically influence response, but no testing is validated for dose selection.
Sex-based considerations: Efficacy data derive almost entirely from men; appropriate dosing in women is unknown and cannot be assumed identical.
Age considerations: No age-specific dosing has been studied; older adults with more medications and lower organ reserve warrant extra caution and monitoring rather than a defined dose adjustment.
Baseline biomarker considerations: Response is likely greatest in those with elevated baseline blood fats; baseline lipids, liver enzymes, and kidney function should inform whether and how the compound is used.
Pre-existing condition considerations: Underlying dyslipidemia or chronic inflammation predicted benefit in trials, whereas liver, kidney, gallbladder, or muscle disease argues against use.

Discontinuation & Cycling

Intended duration: Whether TTA is best used short-term or long-term is unresolved. All human trials lasted only 4 weeks, so any long-term or lifelong use is entirely unstudied and should be regarded as experimental.
Withdrawal effects: No withdrawal syndrome has been described. As a metabolic signaling molecule rather than a dependence-forming drug, abrupt cessation is not expected to cause withdrawal, but blood-fat improvements would likely reverse once dosing stops, as with other fat-lowering agents.
Tapering: No tapering protocol has been studied or is thought necessary; the compound can in principle be stopped without a taper.
Cycling: Whether cycling preserves efficacy or reduces risk is unknown. A theoretical argument for periodic breaks is to allow omega-3 fatty acid levels — which TTA appears to deplete — to recover, but no data support any particular cycling schedule.

Sourcing and Quality

Regulatory and supply status: TTA is not an approved drug or a mainstream dietary supplement. It circulates as a niche “research chemical” and gray-market powder, meaning quality is not guaranteed by any regulator and product identity and purity can vary widely.
What to look for: Because supply is unregulated, a recent third-party certificate of analysis (COA) confirming identity and purity (research-grade material is typically specified at ≥97–98%) is the single most important quality signal. Analytical-grade reference material (for example, from major chemical suppliers such as Sigma-Aldrich) exists but is sold for laboratory use, not consumption.
Reputable sources: There are no established, reputable consumer brands or compounding pharmacies producing TTA to pharmaceutical standards. This absence is itself a meaningful quality limitation, and buyers cannot rely on brand reputation as they might for common supplements.
Formulation: TTA is a free fatty acid; as with other fatty acids, taking it with dietary fat is expected to aid absorption. No standardized, tested consumer formulation exists.

Practical Considerations

Time to effect: Blood-fat and inflammation changes in the human trials emerged over about 4 weeks of daily use; the phase-1 study found no lipid change after only 7 days, so meaningful effects should not be expected within the first week.
Common pitfalls: The most common mistakes are expecting rapid or dramatic results, sourcing unverified powder of unknown purity, using it without baseline and follow-up lab monitoring, combining it with statins, and overlooking its tendency to deplete beneficial omega-3 fats.
Regulatory status: TTA is investigational and not approved by the FDA or comparable agencies for any use; it has no recognized dietary-supplement status. Sale and possession occupy a legal gray area, and any use is off-label and self-directed.
Cost and accessibility: Availability is limited to a small number of specialty and gray-market vendors, which constrains access and makes independently verified quality hard to obtain; it is more difficult to source responsibly than mainstream supplements.

Interaction with Foundational Habits

Sleep: Interaction direction: none established. No human or animal data link TTA to sleep quality or disruption, and its mechanism gives no clear reason to expect a direct effect. Any influence would be indirect, via improved metabolic health.
Nutrition: Interaction direction: direct and bidirectional. As a fatty acid, TTA is reasonably taken with a fat-containing meal to aid absorption. Mechanistically it counteracts high-fat-diet effects in animals, but it also depletes omega-3 fats (DHA and EPA) in people, so pairing it with omega-3-rich foods or fish oil is a sensible practical step. It has no known requirement for a specific diet.
Exercise: Interaction direction: potentially potentiating. TTA and endurance exercise both increase fatty acid oxidation and mitochondrial density, partly through the same PPAR-δ pathway, raising the plausible (but untested) possibility of additive metabolic effects. Practically, no timing relative to workouts has been studied; the theoretical overlap suggests it would complement rather than blunt endurance training.
Stress management: Interaction direction: indirect. TTA’s anti-inflammatory action could theoretically ease the inflammatory component of chronic stress, but no data address cortisol or the stress response directly, so any benefit here is speculative.

Monitoring Protocol & Defining Success

Given the class-based liver, muscle, and kidney risks and the unregulated supply, baseline laboratory testing before starting is prudent, followed by periodic monitoring during use.

Baseline testing should establish a full lipid panel, liver and muscle enzymes, kidney function, blood glucose control, an inflammation marker, and omega-3 status, so that both efficacy and safety can be tracked against a personal starting point rather than population averages.

Ongoing monitoring is reasonable at roughly 4 weeks after starting (to catch early liver or muscle effects and confirm a lipid response), again at about 12 weeks, and then every 3–6 months with continued use.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
LDL cholesterol	<100 mg/dL (lower if high cardiovascular risk)	Primary efficacy target; TTA’s clearest human effect	Fasting preferred; part of a full lipid panel
Triglycerides	<100 mg/dL	Storage-fat marker responsive to TTA	Requires 10–12 h fasting; alcohol the night before skews results
HDL cholesterol and LDL/HDL ratio	HDL >50 mg/dL; LDL/HDL <2.0	Captures the ratio improvement seen in trials	Pair with LDL and triglycerides
ALT and AST (liver enzymes)	ALT <25 U/L (men) / <20 U/L (women); AST <25 U/L	Detects class-based liver stress	Functional targets are tighter than conventional labs (often <40 U/L); recheck if rising
Creatine kinase (CK)	30–150 U/L	Detects muscle toxicity, especially with statins	Avoid strenuous exercise 48 h before testing to prevent false elevation
Creatinine and eGFR (kidney function)	eGFR >90 mL/min/1.73 m²	Class agents can raise creatinine	Best with a basic metabolic panel; hydration affects values
Fasting glucose and HbA1c	Glucose 70–90 mg/dL; HbA1c <5.4%	Confirms no adverse glucose effect (trials showed none)	HbA1c reflects ~3-month average; no fasting needed
hs-CRP (inflammation)	<1.0 mg/L	Tracks the anti-inflammatory signal	Avoid testing during acute illness or injury, which transiently raises it
Omega-3 index (EPA + DHA)	>8% of red-cell fatty acids	TTA depletes omega-3s; guides fish-oil pairing	Reflects longer-term intake; not affected by a single meal

Qualitative markers of success are worth tracking alongside labs:

Energy levels and exercise tolerance
Appetite and any changes in body composition
Skin or joint inflammation (relevant given the psoriasis findings)
General well-being and absence of muscle pain or upper-right abdominal discomfort (early warning signs of class side effects)

Emerging Research

Research on tetradecylthioacetic acid in humans has been largely dormant since the early 2010s, and the emerging picture is defined more by unanswered questions than by active programs. Findings are framed for a metabolically motivated adult weighing whether the science is moving toward, or away from, supporting use.

Registered clinical trials: Only one TTA trial is registered on ClinicalTrials.gov — NCT00605787, a completed phase-2 study (16 participants) of TTA in type 2 diabetes and dyslipidemia, which produced the lipid-lowering results discussed above. No trials are currently recruiting or ongoing, so the near-term human evidence base is unlikely to expand without new sponsorship.
Cholesterol particle remodeling (could strengthen the case): Work by Lundåsen et al., 2020 showed that TTA shifts cholesterol toward larger, potentially more protective HDL particles in a preclinical model, suggesting benefits beyond simple LDL lowering. Confirmation of this particle-level effect in humans would materially strengthen the cardiovascular rationale.
Anti-inflammatory and anti-atherosclerotic mechanisms (could strengthen the case): Studies such as Dyrøy et al., 2005 established that TTA’s anti-inflammatory effects operate through both PPAR-α-dependent and PPAR-α-independent routes, and animal work has shown reduced plaque formation. Further mechanistic and outcome studies could clarify whether these translate to human vascular protection.
Metabolic and fatty-liver applications (could strengthen or weaken the case): Given TTA’s drive on fat oxidation, fatty liver disease (now termed metabolic dysfunction-associated steatotic liver disease, MASLD) is a logical future target; Madsen et al., 2002 provides the preclinical basis in diet-induced obesity. A well-powered human trial could equally reveal that the modest lipid effects do not yield clinical benefit, weakening the case.
Omega-3 depletion as a limitation (could weaken the case): The consistent finding that TTA lowers DHA and EPA in humans, seen in the diabetes trial, is a direction of research that could temper enthusiasm if long-term use proves to erode the benefits of these fats; this warrants dedicated study before extended use is considered reasonable.
Key open questions: Whether TTA produces any hard clinical outcome (cardiovascular events, liver-fat reduction) in humans, its long-term safety beyond four weeks, and its effects in women all remain unanswered and would be needed to change current understanding.

Conclusion

Tetradecylthioacetic acid is a laboratory-made fatty acid that the body cannot burn for fuel, so instead it acts as a lasting signal that switches on fat-burning genes and calms inflammation. In animals and human cells it convincingly increases fat burning, and in a handful of small, short human studies it modestly lowered “bad” cholesterol and triglycerides and reduced markers of inflammation. Those human effects were real but small, came from fewer than sixty people, mostly men, over only four weeks, and did not improve blood sugar or body weight.

Set against this modest promise are meaningful uncertainties. The safety record is short and reassuring only for brief use; most serious concerns — liver stress, muscle injury, gallstones, and depletion of beneficial omega-3 fats — are carried over from closely related fat-lowering drugs or from animal studies rather than proven in people. Supply is unregulated, quality is hard to verify, and no approved product or expert protocol exists.

The overall evidence base is thin and largely produced by a single research group and its commercial sponsor, whose direct financial interest in the compound is a conflict of interest to weigh, with development long stalled rather than the compound being disproven. For now, tetradecylthioacetic acid is best understood as an intriguing, biologically plausible, but unproven candidate whose real long-term value and safety in humans remain genuinely unknown.

Top - Benefits - Risks - Protocol

Tetradecylthioacetic Acid for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Medium 🟩 🟩

Improvement of Blood Lipid Profile

Low 🟩

Reduction of Inflammatory Markers

Increased Fatty Acid Oxidation and Mitochondrial Activity

Speculative 🟨

Protection Against Fat Gain and Insulin Resistance

Cardiovascular and Anti-Atherosclerotic Protection

Antioxidant Protection

Benefit-Modifying Factors

Potential Risks & Side Effects

Low 🟥

Mild Gastrointestinal and General Adverse Events

Depletion of Beneficial Omega-3 Fatty Acids

Speculative 🟨

Liver Enzyme Elevation and Hepatic Effects

Muscle Toxicity, Especially With Statins

Gallstones, Kidney Markers, and Homocysteine

Rodent Liver Tumors (Species-Specific Concern)

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion